Meghan Seltzer

Meghan Seltzer is a Technical Assessor with The MITRE Corporation. She earned a bachelor’s degree in Biochemistry and Molecular Biology from the Pennsylvania State University, a doctorate in Cellular and Molecular Medicine from Johns Hopkins University School of Medicine, and a master’s degree in Management, Strategy, and Leadership from Michigan State University. Meghan is a Registered Biosafety Professional and began her biosafety career as a fellow in the National Biosafety and Biocontainment Training Program. After completing her fellowship, she worked at HHMI’s Janelia Research Campus as a manager in the Safety, Health, and Security department. During her tenure at HHMI, she was responsible for biosafety and occupational health programs as well as various research compliance efforts including IACUC, CLIA, dangerous goods shipping, import/export compliance, IRB, and IBC. Meghan is active in ABSA and ChABSA where she has served on numerous committees and council for both organizations.

MITRE Corporation
Tuesday
May 06
The BESST Approach: Harnessing Private Public Partnerships to Reduce Risk
11:04 AM

-

11:08 AM

Biotechnologies offer immense promise to address complex problems facing society. However, as biotechnologies and the associated industry grow and evolve, so does the associated threat landscape. At times, the threat landscape is so complex and nebulous that individual companies often lack the resources to understand and mitigate threats. Public-private partnerships (PPP) offer proven models to bring companies together to address common, complex challenges. Therefore, we propose establishing a PPP—the BioEconomy Safety, Security, and Technology (BESST) Partnership—to aid industry in identifying and characterizing common threats and developing evidence-based risk mitigation strategies.

Conference Pass

2,495

USD

Keynotes & Firesides

Workshops & Breakouts

1:1 Partnering App

Meals & Receptions

Session Recordings

Until Friday April 18th

Full Rate:

$3,495

Other Speakers

Copyright SynBioBeta 2025